Recce Pharmaceuticals Signs Licensing Deal for R327G in MENA Region
Recce Pharmaceuticals has signed a non-binding term sheet for an exclusive 10-year licensing deal to commercialize its R327 Topical Gel across the Middle East and North Africa (MENA) region. The agreement, with a leading publicly listed pharmaceutical company from the Middle East, aims to address high demand in diabetic foot infection treatments.
Topics: Diabetes Treatments MENA Market Expansion Pharmaceuticals